Study: More MSLs build, maintain relationships with KOLs on reimbursement committees

Published on September 7, 2013 at 6:48 AM · No Comments

Medical science liaisons (MSLs) are increasingly forming relationships with key opinion leaders (KOLs) who serve on reimbursement committees, according to a study by Cutting Edge Information.

“MSL Activities and Performance Measurement: Harnessing KOL Relationships for Optimal Clinical Support”

The study, "MSL Activities and Performance Measurement: Harnessing KOL Relationships for Optimal Clinical Support," found that 67% of MSL teams build and maintain relationships with key decision makers on reimbursement committees. Increasingly, payer organizations, such as health insurance companies, contract with KOLs to serve on committees or panels that determine reimbursement choices.

These decisions include formulary inclusion, price points and drug tiering. Naturally, pharmaceutical companies want to improve their relationships with those KOLs who serve on these panels, although meetings with these individuals typically focus on delivering health economics or outcomes data to the opinion leaders.

"Key opinion leaders serving on reimbursement panels certainly have an increased interest in pharmacoeconomic data in addition to the usual presentations made by medical science liaison teams," said Ryan McGuire, research team leader at Cutting Edge Information. "Of course, market access teams are already responsible for working on reimbursement issues. MSLs must strike a delicate balance to not overstep their responsibilities. Still, more and more, market access teams request assistance from MSL groups."

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment